N-acetylcystein in the therapy of chronic bronchitis;N-acetylcystein in der therapie der chronischen bronchitis

Pneumologie

Volumn 56, Issue 12, 2002, Pages 793-797

  Reichenberger, F ^a,b   Tamm, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIOXIDANT;

ADULT; AGED; BACTERIUM CULTURE; CHRONIC BRONCHITIS; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; ERADICATION THERAPY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; LUNG FUNCTION; MALE; MUCOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SOCIOECONOMICS; SPUTUM CULTURE; SYMPTOM;

EID: 0036955393     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36122     Document Type: Review

References (39)

1. Hurd S. The Impact of COPD on Lung Health Worldwide. Epidemiology and Incidence. Chest 2000; 177: 1-4
2. Pauwels R. COPD. The Scope of the Problem in Europe. Chest 2000; 117: 332-335
3. Niewoehner DE, Erbland ML Deupree RH et al. Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1941-1947
4. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHBLI/WHO Workshop Report. NIH Publication 2701 National Heart, Lung, and Blood Institute, National Institute of Health, April 2001
5. Wettengel R, Böhning W, Cegla U et al. Empfehlung der Deutschen Atemwegsliga zur Behandlung von Patienten mit Chronisch Obstrukriver Bronchitis und Lungenemphysem. Med Klein 1995; 90: 3-7
6. Leuenberger P, Anderhub HP, Brändli O et al. Management 1997 of Chronic Obstructive Pulmonary Disease. Schweiz Med Wochenschr 1997; 127: 766-782
7. Report of an expert committee: Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysema. WHO Techn Rep Ser 1961; 213: 14-19
8. Clarke SW. Management of Mucus Hypersecretion. Eur J Respir Dis Suppl 1987; 153: 136-144
9. Rubin BK. The pharmacologic approach to airway clearance: Muco-active agents. Respir Care Jul 2002; 47(7): 818-822
10. Tunek A. Possible mechanism behind the anti-inflammatory effects of N-Acetylcysteine: Is metabolism essential? Eur Respir J 1992; 2: 35-38
11. Gillissen A, Nowak D. Characterization of N-Acetylcysteine and Ambroxol in Antioxidant Therapy. Respir Med 1998; 92: 609-623
12. Meister R. Bronchopulmonale Protektion - Theorie und Praxis. NAC bei chronischer Bronchitis und Lungenemphysem. Atemw Lungenkrkh 1991; 17: 43-56
13. Siafkas NM, Vermeire P, Pride NB et al. Optimal Assessment and Management of Chronic Obstructive Pulmonary Disease. Eur Respir J 1995; 8: 1398-1420
14. American Thoracic Society. Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1995; 152: 77-121
15. Ranasinha C, Assoufi B, Shak S et al. Efficacy and safety of Short-Term Administration of Aerosolised Recombinant Human DNAse 1 in Adults with Stable Stage Cystic Fibrosis. Lancet 1993; 342: 199-202
16. Puchelle E, Zahm JM, de Bentzmann S et al. Effects of rhDNAse on Purulent Airway Secretions in Chronic Bronchitis. Eur Respir J 1996; 9: 765-769
17. Barnes PJ. New Therapies for Chronic Obstructive Pulmonary Disease. Thorax 1998; 53: 137-147
18. Repine JE, Bast A, Lankhorst I. Oxidative Stress in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1997; 156: 341-357
19. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of Radiographic-Contrast-Agent - Induced Reductions in Renal Function by Acetylcysteine. New Engl J Med 2000; 343: 180-184
20. Behr J, Maier K, Degenkolb B et al. Antioxidative and Clinical Effects of High-dose N-Acetylcysteine in Fibrosing Alveolitis. Am J Respir Crit Care Med 1997; 156: 1897-1901
21. Kasielski M, Nowak D. Long-term administration of N-Acetylcysteine Decreases Hydrogen Peroxide Exhalation in Subjects with Chronic Obstructive Pulmonary Disease. Respir Med 2001; 95: 448-456
22. Grandjean EM, Berthet PH, Ruffmann R et al. Efficacy of oral Longterm N-Acetylcysteine in Chronic Bronchopulmonary Disease: A Meta-Analysis of Published Double-Blind, Placebo-Controlled Clinical Trials. Clinical Therapeutics 2000; 22: 209-221
23. Pela R, Calcagni AM, Subiaco S et al. N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD. Respiration 1999; 66: 495-500
24. Stey C, Steurer J, Bachmann S et al. The Effect of Oral N-Acetylcysteine in Chronic Bronchitis: a Quantitative Systematic Review. Eur Respir J 2000; 16: 253-262
25. Lindström M, Lundbäck B, Lundquist A et al. N-Acetylcystein Improves Quality of Life in Chronic Bronchitis. Eur Respir J 1996; 9: 305-306
26. Poole PJ, Black PN. Oral Mucolytic Drugs for Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. BMJ 2001; 322: 1271-1274
27. Cabello H, Torres A, Cells R et al. Bacterial Colonization of Distal Airways in Healthy Subjects and Chronic Lung Disease: a Bronchoscopic Study. Eur Respir J 1997; 10: 1137-1144
28. Riise GC, Larsson S, Larsson P et al. The Intrabronchial Microbial Flora in Chronic Bronchitis Patients: a Target for N-Acytylcysteine Therapy? Eur Respir J 1994; 7: 94-101
29. Riise GD, Qvarfordt I, Larsson S et al. Inhibitory Effect of N-Acetylcysteine on Adherence of Streprococcus pneumoniae and Haemophilus influenzae to Human Oropharyngeal Epithelial Cells in vitro. Respiration 2000; 67: 552-558
30. Sachs AP, Koeter GH, Groenier KH et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-763
31. Tamm M, Perruchoud AP. Bakterielle Eradikation bei Patienten mit COPD: Prospektive randomisierte offene Pilotstudie mit Amoxicillin/Clavulansäure versus Amoxicillin/Clavulansäure kombiniert mit N-Acetylcystein. Schweiz Med Wochenschr 1997; 127 Suppl 84: 15
32. Lundbäck B, Lindström M, Andersson S et al. Possible Effect of Acetylcystein on Lung Function. Eur Respir J 1992; 5 Suppl 15: 189
33. Van Schayk CP, Dekhuijzen PNR, Gorgels WJM et al. Are Anti-oxidant and Anti-inflammatory Treatment Effective in Different Subgroups of COPD? Respir Med 1998; 92: 1259-1264
34. Rubio ML, Sanchez-Cifuentes MV, Ortega M et al. N-Acetylcysteine Prevents Cigarette Smoke Induced Small Airways Alterations in Rats. Eur Respir J 2000; 15: 505-511
35. Hida W, Shindo C, Satoh J et al. N-Acetylcysteine Inhibits Loss of Diaphragm Function in Streptozotocin-treated Rats. Am J Respir Crit Care Med 1996; 153: 1875-1879
36. Supinski G. Free Radical induced Respiratory Muscle Dysfunction. Mol Cell Biochem 1998; 179: 99-110
37. Grandjean EM, Berthet PH, Ruffmann R et al. Cost-Effectiveness Analysis of Oral N-Acetylcysteine as a Preventive Treatment in Chronic Bronchitis. Pharmacol Research 2000; 42: 39-50
38. Rasmussen JB, Glennow C. Reduction in Days of Illness after Longterm Treatment with N-Acetylcysteine Controlled-release Tablets in Patients with Chronic Bronchitis. Eur Respir J 1988; 1: 351-355
39. Decramer M, Dekhuijzen PN, Troosters T et al. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): Hypothesis and Design. BRONCUS-trial Committee. Eur Respir J 2001; 17: 329-336